"Obesity - Pipeline Review, H2 2012" Published

Sept. 20, 2012 - PRLog -- Global Markets Direct's, 'Obesity - Pipeline Review, H2 2012', provides an overview of the Obesity therapeutic pipeline. This report provides information on the therapeutic development for Obesity, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Obesity. 'Obesity - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

------------------------------------------------------------
Full Report Details at
- http://www.fastmr.com/prod/463830_obesity_pipeline_review_h2_2012.aspx
------------------------------------------------------------

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

* A snapshot of the global therapeutic scenario for Obesity.
* A review of the Obesity products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
* Coverage of products based on various stages of development ranging from discovery till registration stages.
* A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
* Coverage of the Obesity pipeline on the basis of route of administration and molecule type.
* Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
* Key discontinued pipeline projects.
* Latest news and deals relating to the products.

Reasons to buy

* Identify and understand important and diverse types of therapeutics under development for Obesity.
* Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
* Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
* Devise corrective measures for pipeline projects by understanding Obesity pipeline depth and focus of Obesity therapeutics.
* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Obesity Therapeutic Products under Development, Key Players in Obesity Therapeutics, Obesity Pipeline Overview, Obesity Pipeline, Obesity Pipeline Assessment

Partial Table of Contents:

Table of Contents
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Obesity Overview
Therapeutics Development
An Overview of Pipeline Products for Obesity
Obesity Therapeutics under Development by Companies
Obesity Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Obesity Therapeutics - Products under Development by Companies
Obesity Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Obesity Therapeutics Development
Bristol-Myers Squibb Company
Boehringer Ingelheim GmbH
F. Hoffmann-La Roche Ltd.
Shionogi & Co., Ltd.
AstraZeneca PLC
Eli Lilly and Company
NeuroSearch A/S
Orchid Chemicals & Pharmaceuticals Ltd
Corcept Therapeutics Incorporated
Arena Pharmaceuticals, Inc.
Emisphere Technologies, Inc.
Unigene Laboratories, Inc.
Theratechnologies Inc.
LG Life Sciences, Ltd
Transition Therapeutics Inc.
Suven Life Sciences Ltd.
Galapagos NV
Phynova Group Ltd
Proximagen Neuroscience plc.
Orexigen Therapeutics, Inc.
Advinus Therapeutics Pvt. Ltd.
Sirtris Pharmaceuticals, Inc.
Jenrin Discovery, Inc.
ObeTherapy Biotechnology
7TM Pharma A/S
Metabolex, Inc
Helsinn Healthcare S.A.
Xenon Pharmaceuticals Inc.
Spherix Incorporated
AngioChem Inc.
Global Health Ventures Inc.
Zafgen Inc.
Ambrx, Inc.
Lithera, Inc.
Sirona Biochem Corp
Reviva Pharmaceuticals Inc.
PharmaIN Corporation
Rhythm Pharmaceuticals
Obesity - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
MEM 68626 - Drug Profile
Cametor - Drug Profile
Qsymia - Drug Profile
Belviq - Drug Profile
5HT2C Agonist - Drug Profile
11BHSD Enzyme Inhibitor - Drug Profile
AEZS-123 - Drug Profile
CSC 500 Series - Drug Profile
TM38837 - Drug Profile
TM30339 - Drug Profile
TGFTX2 Program - Drug Profile
GFT505 - Drug Profile
Nuclear Receptor Program - Drug Profile
Leptin - Drug Profile
NOX-B11 - Drug Profile
SGLT-2 Inhibitor - Drug Profile
OAP-189 - Drug Profile
JD-2000 Series - Drug Profile
Velneperit - Drug Profile
Victoza - Drug Profile
ALB-127158(a) - Drug Profile
FAS89B - Drug Profile
FAS 267 - Drug Profile
ZYD1 - Drug Profile
SRT1720 - Drug Profile
TA-7284 - Drug Profile
Xenical - Drug Profile
HPP404 - Drug Profile
PRX00933 - Drug Profile
KGT-1681 - Drug Profile
LIPO-102 - Drug Profile
Leptin - Drug Profile
Botox - Drug Profile
Exenatide - Drug Profile
A-100 - Drug Profile
Betahistine - Drug Profile
Byetta - Drug Profile
Metformin - Drug Profile
BGP-15 - Drug Profile
Diazoxide - Drug Profile
Drug For Obesity - Drug Profile
S-234462 - Drug Profile
2-Hydroxyoleic Acid - Drug Profile
Betahistine - Drug Profile
Metformin - Drug Profile

Full Table of Contents is available at:
-- http://www.fastmr.com/catalog/product.aspx?productid=4638...

About Global Markets Direct

Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.